Recent Updates
Recently added Catalysts
GKOS Positive Sentiment

Glaukos Announces Positive Topline Results from Phase 4 Prospective Randomized Controlled Clinical Trial Evaluating iDose® TR in Combination with Cataract Surgery

Friday, October 9, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Glaukos Corporation has reported positive topline results from its Phase 4 clinical trial (GLK-101-04) assessing the iDose® TR in combination with cataract surgery. The trial evaluated its effectiveness in patients with open-angle glaucoma compared to cataract surgery alone. These findings suggest a potential advancement in glaucoma treatment options.

Market Sentiment Analysis

POSITIVE FACTORS

  • Positive topline results from the Phase 4 trial.
  • iDose® TR shows promise when combined with cataract surgery.
  • Potential improvement in treatment for open-angle glaucoma patients.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+66%
120-day peak, hindsight
Typical move
8.7%
average across 4 past catalysts
Lead asset
Test Article A
Phase 3 · Progressive Keratoconus

Full Press Release Details

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced positive topline results from the Phase 4 prospective, randomized, controlled clinical trial (GLK-101-04) evaluating iDose® TR administered in conjunction with cataract surgery compared to cataract surgery alone in patients with open-angle glaucoma (OA

Frequently Asked Questions

What were the results of the Phase 4 trial?

The Phase 4 trial reported positive topline results for iDose® TR.

What is iDose® TR used for?

iDose® TR is evaluated for treating open-angle glaucoma.

What does the trial compare?

It compares iDose® TR with cataract surgery to surgery alone.

Who conducted the clinical trial?

The trial was conducted by Glaukos Corporation.

ShareAdd on Google
Tags: GKOS Glaukos iDose TR Phase 4 trial cataract surgery open-angle glaucoma
Last updated: Oct 9, 2026

Biotech snapshot

Cash runway
$286M liquidity · $0M/mo burn
Low dilution risk
Lead asset
Test Article APhase 3
Progressive Keratoconus →

Catalyst track record

+66%
best trade around GKOS's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for GKOS.

See every catalyst's timing & PoA →